Dergiler / Haseki Tıp Bülteni / 2022 / Cilt: 60 - Sayı: 1

Efficacy of Prothrombin Complex Concentrate versus Fresh Frozen Plasma in Patients with Bleeding in the Emergency Department

Sayfa
64–71
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: FFP is preferable in this regard to FFP because it is easier to apply, has a faster effect, and provides better values in coagulation parameters.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: It is important to determine which of the treatment options applied in the emergency department is more effective and usable in coagulation pathologies.
📊
Temel Bulgular & Veri:In this study, we aimed to evaluate the efficacy and safety of fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC), which are used in the treatment of high hemostasis parameters in the emergency department.
💡
Sonuç & Katkı:Conclusion: FFP is preferable in this regard to FFP because it is easier to apply, has a faster effect, and provides better values in coagulation parameters.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: It is important to determine which of the treatment options applied in the emergency department is more effective and usable in coagulation pathologies. In this study, we aimed to evaluate the efficacy and safety of fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC), which are used in the treatment of high hemostasis parameters in the emergency department. Methods: This retrospective study included 103 patients who were admitted to the emergency department between January 2019 and December 2020. All data were obtained from the hospital automation system. While the patients were divided into two groups (FFP-PCC) according to the treatment option they received, they were also divided into three groups (DED-RSH-ISH) according to hospitalization status. With this data, treatment efficacy and outcomes were analyzed. Results: The mean age of 103 patients was 67.31±13.17 years, with 58 (56%) females and 45 (44%) males. 51 (49.5%) of the cases received FFP and 52 (50.5%) PCC treatment. While the international normalized ratio (INR)1 value before the treatment was 7.56±4.09 and 2.42±1.01 after the treatment in the FFP group, the INR1 value was 10.12±5.18 and INR2 1.95±0.71 in the PCC group. The percentage of INR decrease was 60.28±19.76 (%) in the FFP group, and 73.41±17.42 (%) in the PCC group (p=0.001). In receiver operating characteristic curve analysis, the sensitivity and specificity of FFP and PCC decreased significantly in INR%. Conclusion: FFP is preferable in this regard to FFP because it is easier to apply, has a faster effect, and provides better values in coagulation parameters.

🔖

Bu Makaleye Atıf Yap

COŞKUN, A., DEMİRCİ, B. (2022). Efficacy of Prothrombin Complex Concentrate versus Fresh Frozen Plasma in Patients with Bleeding in the Emergency Department. Haseki Tıp Bülteni, Cilt: 60 - Sayı: 1, 64–71. https://ajindex.com/articles/534947

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Greaves M, Watson HG. Approach to the diagnosis and management of mild bleeding disorders. J Thromb Haemost 2007;5:167-74
  2. Altunbaş G, Ercan S, Davutoğlu V, Al B. Overview of Warfarin Treatment and Answers to Questions. Eurasian J Emerg Med 2013;12:38-42
  3. Chapman SA, Irwin ED, Beal AL, Kulinski NM, Hutson KE, Thorson MA. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother 2011;45:869-75
  4. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013;128:1234-43
  5. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation):Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014;63:2141-7
  6. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009;124:37-41
  7. Ozgonenel B, O’Malley B, Krishen P, Eisenbrey AB. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007;82:1091-4
  8. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84:326-31
  9. Carlquist JF, Horne BD, Mower C, et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J Thromb Thrombolysis 2010;30:358-64
  10. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009;108:1433-46
  11. Green L, Roberts N, Cooper J, et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery – a pilot randomised controlled trial (PROPHESY trial). Anaesthesia 2021;76:892-901
  12. Kao TW, Lee YC, Chang HT. Prothrombin Complex Concentrate for Trauma Induced Coagulopathy: A Systematic Review and Meta-Analysis. J Acute Med 2021;11:81-9
  13. Bouzat P, Bosson JL, David JS, et al. Four-factor prothrombin complex concentrate to reduce allogenic blood product transfusion in patients